Abstract
2-Phenyl-5,6-dihydroxypyrimidine-4-carboxylic acids were discovered as specific inhibitors of the NS5B polymerase of the Hepatitis C Virus. In-depth structure-activity investigations at the ortho and meta positions of the phenyl ring were undertaken, and compounds with greatly improved activity over the original lead have been discovered.
Keywords: hcv ns5b rna polymerase, dihydroxypyrimidines, sar, inhibitors, amides, ureas
Letters in Drug Design & Discovery
Title: Phenyldihydroxypyrimidines as HCV NS5B RNA Dependent RNA Polymerase Inhibitors. Part I: Amides and Ureas
Volume: 2 Issue: 6
Author(s): B. Crescenzi, M. Poma, J. M. Ontoria, A. Marchetti, E. Nizi, V. G. Matassa and C. Gardelli
Affiliation:
Keywords: hcv ns5b rna polymerase, dihydroxypyrimidines, sar, inhibitors, amides, ureas
Abstract: 2-Phenyl-5,6-dihydroxypyrimidine-4-carboxylic acids were discovered as specific inhibitors of the NS5B polymerase of the Hepatitis C Virus. In-depth structure-activity investigations at the ortho and meta positions of the phenyl ring were undertaken, and compounds with greatly improved activity over the original lead have been discovered.
Export Options
About this article
Cite this article as:
Crescenzi B., Poma M., Ontoria M. J., Marchetti A., Nizi E., Matassa G. V. and Gardelli C., Phenyldihydroxypyrimidines as HCV NS5B RNA Dependent RNA Polymerase Inhibitors. Part I: Amides and Ureas, Letters in Drug Design & Discovery 2005; 2 (6) . https://dx.doi.org/10.2174/1570180054771491
DOI https://dx.doi.org/10.2174/1570180054771491 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Preface
Current Pharmaceutical Design c-Myc Inhibitor 10074-G5 Induces Murine and Human Hematopoietic Stem and Progenitor Cell Expansion and HDR Modulator Rad51 Expression
Current Cancer Drug Targets Alzheimer’s Disease: Physical Activities as an Effective Intervention Tool - A Mini-Review
Current Alzheimer Research Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Therapeutic Strategies for Treatment of Inflammation-related Depression
Current Neuropharmacology Cytokine, Chemokine, and Costimulatory Molecule Modulation to Enhance Efficacy of HIV Vaccines
Current Molecular Medicine Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design Fed Batch Fermentation and Purification Strategy for High Yield Production of Brucella melitensis Recombinant Omp 28 kDa Protein and its Application in Disease Diagnosis
Protein & Peptide Letters Vaccination Against High Blood Pressure
Current Pharmaceutical Design Purinergic Receptors and Pain
Current Pharmaceutical Design Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience The Effects of D-aspartate on Neurosteroids, Neurosteroid Receptors, and Inflammatory Mediators in Experimental Autoimmune Encephalomyelitis
Endocrine, Metabolic & Immune Disorders - Drug Targets Serotonin and Human Cognitive Performance
Current Pharmaceutical Design Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A
Current Cancer Drug Targets Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design